The introduction of protocols for reprogramming all somatic cells into pluripotent stem cells has allowed induced pluripotent stem cells (iPSCs) to be generated from every patient and healthy donor. Since pluripotent stem cells can be used to generate any cell type in culture, this technology has been revolutionizing the field of regenerative medicine, especially in combination with CRISPR genome engineering.
The iPSC/CRISPR facility was established in 2016 and supports scientists and clinicians in generating iPSCs. In this facility, researchers developed protocols to alter the genome of the iPSCs based on CRISPR genome engineering technology. This allows the generation of, for instance, patient-derived stem cells and differentiated progeny in which a pathogenic DNA mutation is repaired. Scientists can subsequently compare cells in which such a pathogenic mutation is repaired with cells in which the mutation is not repaired, to improve our molecular understanding of disease.
For more information, please visit: iPSC/CRISPR facility.